Serotonin Syndrome Risks With Co-Prescription of Triptan Drugs and SSRIs or SNRIs
The Carlat Psychiatry Report, Volume 16, Number 9, September 2018
Adam Strassberg, MD.
Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In 2006, the FDA issued a warning that patients using either selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors (SSRIs or SNRIs) together with triptan antimigraine drugs might be at a heightened risk for serotonin syndrome.